Madrigal Pharmaceuticals (MDGL) Total Liabilities (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Total Liabilities of $720.9 million for Q2 2026, up 125.71% year-over-year from $319.4 million in Q2 2025, and up 5.42% quarter-over-quarter from $683.9 million in Q1 2026.
Madrigal Pharmaceuticals (MDGL) Total Liabilities (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Total Liabilities for 17 consecutive years, with $720.9 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Total Liabilities rose 125.71% year-over-year to $720.9 million; the TTM figure through Jun 2026 stood at $720.9 million (up 125.71% YoY), while the FY2025 annual figure was $656.9 million, up 128.2% from the prior year.
- Total Liabilities advanced to $720.9 million in Q2 2026 per MDGL's latest filing, from $683.9 million in the prior quarter.
- Across five years, Total Liabilities topped out at $736.7 million in Q3 2025 and bottomed at $76.9 million in Q1 2022.
- Historically, Total Liabilities has averaged $323.2 million across 5 years, with a median of $238.9 million in 2023.
- Annual changes were most pronounced in 2024 — Total Liabilities gained 21.97% — and 2025, when it jumped 148.8%.
- Madrigal Pharmaceuticals' Total Liabilities stood at $165.2 million in 2022, then soared by 42.4% to $235.2 million in 2023, then advanced by 22.38% to $287.9 million in 2024, then jumped by 128.2% to $656.9 million in 2025, then advanced by 9.75% to $720.9 million in 2026.
- Business Quant data shows MDGL's Total Liabilities at $720.9 million in Q2 2026, $683.9 million in Q1 2026, and $656.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Madrigal Pharmaceuticals | 14.79 Bn | 13.95 Bn | - | 720.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 720.92 Mn |
| Mar 31, 2026 | 683.87 Mn |
| Dec 31, 2025 | 656.90 Mn |
| Sep 30, 2025 | 736.73 Mn |
| Jun 30, 2025 | 319.40 Mn |
| Mar 31, 2025 | 285.99 Mn |
| Dec 31, 2024 | 287.86 Mn |
| Sep 30, 2024 | 296.11 Mn |
| Jun 30, 2024 | 242.67 Mn |
| Mar 31, 2024 | 231.52 Mn |
| Dec 31, 2023 | 235.21 Mn |
| Sep 30, 2023 | 215.72 Mn |
| Jun 30, 2023 | 198.96 Mn |
| Mar 31, 2023 | 182.31 Mn |
| Dec 31, 2022 | 165.18 Mn |
| Sep 30, 2022 | 147.97 Mn |
| Jun 30, 2022 | 132.86 Mn |
| Mar 31, 2022 | 76.92 Mn |
| Dec 31, 2021 | 77.23 Mn |
| Sep 30, 2021 | 69.82 Mn |